Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer
British Journal of Biomedical Science · 2026
DOI: 10.3389/bjbs.2026.16709 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Biomedical Science, 2026. Verfasst von Muhammad Talal Amin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Data Analysis and Mathematical Modelling, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Genomic Imprinting, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Genomic imprinting is the phenomenon in which only a single allele of a gene is expressed based on its parental origin, thereby deviating from the typical biallelic expression of autosomal genes. It is meticulously controlled by epigenetic mechanisms, particularly DNA methylation. Imprinted loci are crucial for regulating growth during early development, and anomalies in imprinting can lead to congenital syndromes such as Beckwith-Wiedemann’s and Prader-Willi’s. Similarly, many cancers exhibit dysregulated imprinting patterns, putatively contributing to tumour growth. Yet, the assessment of imprinting in cancer is complex due to technical challenges, impeding clinical research and the translation of novel insight to the clinic. This review starts with a general introduction to imprinting, its (dys)regulation and key clinical findings in cancer and beyond. Then, we summarize common methods used to characterize normal imprinting and aberrations in cancer. Subsequently, we discuss how the interpretation of such findings is complicated by technical challenges, such as tumour impurity, the requirement for heterozygosity to distinguish between maternal and paternal alleles and the presence of tissue- and transcript-specific imprinting patterns. We further delve into state-of-the-art methods able to mitigate these challenges. Finally, we discuss how future methodological innovations, particularly by integrating single-cell and single-molecule based methods, may further facilitate a straightforward characterization of imprinting dysregulation and its underlying causes, and guide the development of clinical tests. Thus, by integrating recent advances and proposing innovative approaches, our review aims to provide a comprehensive overview for cancer researchers and clinicians to facilitate cancer imprinting research and its translation to the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Data Analysis and Mathematical Modelling, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.
- Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
- Department of Bioscience and Technology, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, Pakistan.
- Bioinformatics Institute Ghent N2N, Ghent University, Ghent, Belgium.
Zitieren
APA
Amin, M. T., Coussement, L., & De Meyer, T. (2026). Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer. British Journal of Biomedical Science. https://doi.org/10.3389/bjbs.2026.16709
Vancouver
Amin MT, Coussement L, De Meyer T. Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer. British Journal of Biomedical Science. 2026. doi:10.3389/bjbs.2026.16709
BibTeX
@article{Amin2026,
author = {Amin, Muhammad Talal and Coussement, Louis and De Meyer, Tim},
title = {Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer},
journal = {British Journal of Biomedical Science},
year = {2026},
doi = {10.3389/bjbs.2026.16709}
}
EUVIMED